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Abstract: Human papillomavirus (HPV) types 16 and 18 cause 70% of cervical cancer
cases globally. The nonavalent HPV vaccine (9vHPV) was licensed in 2014 and protects
against the next ﬁve most common cancer-causing HPV types (HPV 31/33/45/52/58) after
HPV 16/18. Phase III clinical studies have demonstrated high vaccine efﬁcacy (>90%)
against cervical, vulvar, and vaginal precancers caused by these additional types, and have
shown comparable immunogenicity to the shared genotypes to quadrivalent HPV vaccine
(4vHPV). Vaccine efﬁcacy and antibody responses for 9vHPVare found to persist for at least
ﬁve years while longer-term observational studies are ongoing to monitor long-term vaccine
effectiveness. The implementation of 9vHPV has the potential to prevent up to 93% of
cervical cancer cases, as well as a signiﬁcant proportion of other HPV-related anogenital
cancers. This review article summarizes the current evidence for 9vHPV in terms of vaccine
efﬁcacy against HPV infection and related anogenital precancers, safety, and immunogeni-
city, as well as discussing the potential impact of this vaccine on the cervical cancer burden
globally.
Keywords: nonavalent human papillomavirus vaccine, review, efﬁcacy, immunogenicity,
safety
Introduction
The human papillomavirus (HPV) vaccines are made using recombinant technology
based on the self-assembly nature of the L1 capsid protein of the virus (viral-like
particles, VLPs). As the VLPs do not contain the viral genome, they are not
infectious. There are currently three licensed prophylactic HPV vaccines against
HPV infections and cervical cancer precursors. The timeline of the Phase III clinical
trials and licensure/registration of HPV vaccines is shown in Figure 1, and countries
that have a national HPV immunization program are shown in Figure 2. The ﬁrst-
generation HPV vaccines, quadrivalent (4vHPV) and bivalent (2vHPV), were ﬁrst
licensed in 2006 and 2007, respectively. Both vaccines protect against HPV types
16 and 18 (major types causing cervical cancers), while 4vHPV also protects
against HPV types 6 and 11 (major types causing genital warts). In 2014, a second-
generation nonavalent HPV vaccine (9vHPV) was licensed by The United States
(U.S.) Food and Drug Administration (FDA) for individuals aged 9–26 years, and
subsequently extended to women up to age 45 years in 2018. This vaccine contains
an additional ﬁve cancer-causing HPV types (HPV31, 33, 45, 52, and 58) in
addition to the four types in 4vHPV, and has the potential to prevent up to 93%
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of cervical cancers.1 This review article summarizes the
efﬁcacy of 9vHPV in preventing HPV infection and related
anogenital precancers as demonstrated in clinical trials to
date, as well as the potential impact of this vaccine on the
cervical cancer burden globally. We searched for studies
and review articles that evaluated the safety, efﬁcacy, and
immunogenicity of 9vHPV using PubMed, Google
Scholar, and scientiﬁc review/comment papers during
August 2018–January 2019, and included them in this
review article. Search terms used include “Gardasil9”,
“nine-valent HPV vaccine”, “burden of cervical cancer”,
“HPV vaccine licensure”, “HPV vaccination”, “HPV vac-
cines”, and “cost-effectiveness”.
Burden of HPV-associated diseases
HPV infection is one of the most common sexually trans-
mitted infections worldwide.2 A meta-analysis of over
one million women from 194 studies found an overall HPV
prevalence of approximately 12% in asymptomatic women
globally.3 The highest HPV prevalence is in the sub-Saharan
African regions (24%), although these estimates vary by
region, study design, as well as age of participants.3 Most
individuals (approximately 90%) infected with HPV are
asymptomatic and are able to clear the infection through
host immune responses within two years.4 However, for the
small proportion who have persistent infection, this can lead
to a range of diseases from benign lesions to anogenital
cancers as well as some oropharyngeal diseases. There are
currently more than 100 HPV genotypes identiﬁed that can
be classiﬁed into high- and low-risk types depending on the
potential neoplastic disease they cause.
Low-risk HPV types 6 and 11 cause 90% of anogenital
warts and benign/low-grade abnormalities in the genital
areas.5,6 These HPV types are also responsible for causing
recurrent respiratory papillomatosis in the respiratory
tract.7 The high-risk HPV types are known to cause ano-
genital cancers, which includethe majority of cervical can-
cer cases and a signiﬁcant proportion of vaginal (78%) and
anal (88%) cancers, as well as some vulvar (25%) and
penile (50%) cancers.8,9 In addition, high-risk types, in
particular HPV16, are also responsible for an increasing
number of oropharyngeal cancers (31%) largely in the
base of the tongue and tonsillar areas.10,11 These diseases
are more common in immunocompromised individuals
such as those infected with HIV or post transplantation.12
Cervical cancer remains the fourth most common cancer
in women worldwide, with an estimated 570,000 cases and
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Figure 1 Timeline of pivotal Phase III HPV vaccine trials and licensure/registration of the HPV vaccines.
Notes: aTwo-dose schedule separated by six months to adolescents aged <15 years. b Data from Iversen et al.57
Abbreviations: 4vHPV, quadrivalent HPV vaccine; 2vHPV, bivalent HPV vaccine; 9vHPV, nonavalent HPV vaccine; FDA, The U.S. Food and Drug Administration; HPV,
human papillomavirus; EU, European Union; VLP, virus-like particle.
Figure 2 Countries that have introduced a national human papillomavirus immu-
nization program using any of the three licensed vaccines (91 countries, 47%).
Source: Data from WHO.85
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311,000 deaths annually.13 The majority of these cases occur
in low-and lower-middle-income countries (LLMICs) due to
multiple factors. These factors include the lack of compre-
hensive cervical cancer screening programs and treatment of
lesions found on screening, no access to HPV vaccine due to
the high vaccine cost, limited health services to deliver these
vaccines, as well as the vaccine being seen as a low
priority.14,15 Moreover, issues such as vaccine hesitancy,
and social and cultural factors have also impeded the intro-
duction of HPV vaccines.14 Globally, HPV16 and 18 are
responsible for 70% of cervical cancer.9 Together with HPV
types 31/33/45/52/58, these nine types are responsible for
approximately 90% of cervical cancers worldwide.8,99 The
prevalence of these ﬁve HPV types varies geographically,
with higher prevalence of HPV52 and 58 in East Asia and
North America, while HPV31, 33 and 45 are more common
in European countries.3,16
First-generation HPV vaccines
The formulations and schedules of 4vHPV and 2vHPV are
summarized in Table 1. Although both vaccines have alu-
minum-based adjuvant, 2vHPV also contains
a monophosphoryl lipid A adjuvant component, which acti-
vates innate immunity through Toll-like receptor 4.17 This
adjuvant system is also known as AS04 and is thought to
account for the higher immunogenicity induced by 2vHPV
when compared with 4vHPV, although the clinical signiﬁ-
cance remains unknown (there has been no breakthrough
disease seen in those vaccinated and thus no deﬁned
immune correlate of protection).18,19 Both 4vHPV and
2vHPV have greater than 90% efﬁcacy against cervical
intraepithelial neoplasia grade 1–3, adenocarcinoma
in situ, and invasive cervical carcinoma due to HPV16/18
in women aged 15–26 years.20–23 Although both vaccines
might provide protection against other HPV-related cancers
such as vulvar, vaginal, and anal,24 only 4vHPV is licensed
against these cancers as well as against HPV6- and HPV11-
related genital warts.
Neutralizing antibodies are thought to be the primary
mediator of protection for HPV vaccines, although to date,
the actual level required for protection (ie, correlate) has not
been identiﬁed. Overall, seroconversion occurs in 99–100%
of those vaccinated in randomized double-blind placebo-
controlled trials.25 Antibody responses following vaccina-
tion peak at month seven (one month after the third dose) at
titers between 10- and 100-fold higher than the levels found
following natural infection.25 Such antibody responses are
found to persist at a level several-fold higher than natural
infection for more than 10 years.26 The high immunogeni-
city of the HPV vaccine is thought to be due to the dense and
ordered structure of the VLPs, as well as the route of
administration in comparison to the natural infection route.27
The high vaccine efﬁcacy observed in vaccinated
young adults (age 16–26 years) not infected or previously
infected with the vaccine HPV types has prompted the use
of HPV vaccine in young adolescents before the onset of
sexual activity. Immunobridging studies evaluating either
4vHPV or 2vHPV in adolescent girls/boys and women
following a three-dose schedule found at least one- to two-
fold higher type-speciﬁc antibodies in the younger age
group.28–30 Moreover, several studies then found that two
doses given to adolescents six months apart had antibody
responses that were non-inferior to women who were
given the standard three-dose schedule, summarized by
Toh et al.31 These studies have led the WHO to revise its
recommendation in 2014 to include a two-dose HPV vac-
cine schedule for girls aged <15 years, provided the inter-
val between each dose is at least six months.32
Both 2vHPV and 4vHPV also provide some degree of
cross-protection to nonvaccine but phylogenetically
related HPV types (ie, HPV31, 33, and 45), which is likely
to be mediated by cross-neutralizing antibodies.33–38 In
Table 1 Characteristics of HPV VLP vaccines
Manufacturer Merck™ (Gardasil®) GlaxoSmithKline™ (Cervarix®) Merck™ (Gardasil® 9)
L1 VLP types 6, 11, 16, and 18 16 and 18 6, 11, 16, 18, 31, 33, 45, 52, and 58
Dose 20/40/40/20 µg 20/20 µg 30/40/60/40/20/20/20/20/20 µg
Producer cells Saccharomyces cerevisiae (baker’s
yeast) expressing L1
Trichoplusia ni (Hi 5) insect cell line infected with
L1 recombinant baculovirus
Saccharomyces cerevisiae (baker’s
yeast) expressing L1
Adjuvant 225 µg aluminium hydroxypho-
sphate sulfate
500 µg aluminium hydroxide, 50 µg
3-O-deacylated-4ʹ-monophosphoryl lipid A
500 µg aluminium hydroxypho-
sphate sulfate
Vaccination schedule 0, 2, and 6 months 0, 1, and 6 months 0, 2, and 6 months
Abbreviations: HPV, human papillomavirus; VLP, virus-like particle.
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most cases, 2vHPV generated signiﬁcantly higher neutra-
lizing antibodies for HPV31 and 45 than 4vHPV, possibly
due to its unique adjuvant properties, although the clinical
signiﬁcance of this is unknown.37,39,40 These cross-
neutralizing antibodies are approximately 100-fold lower
than vaccine-type antibodies,41 which raises the question
of the duration of protection against these nonvaccine
types.
Vaccine efﬁcacy of 9vHPV
The appeal of 9vHPV is the potential to protect against the
nine most common cancer-causing HPV types, as well as
the majority of genital warts cases. Since 9vHPV was only
licensed in the last ﬁve years and rollout in public health
programs is only recent, population data are still several
years away. Phase III studies have demonstrated that
9vHPV is safe and highly efﬁcacious against HPV infec-
tion and anogenital precancer lesions in both men and
women (Table 2). Of note, the pivotal trial that led to the
licensure of 9vHPV was an international multicenter, dou-
ble-blind randomized controlled trial of more than 10,000
women aged 16–26 years. The study reported greater than
96% vaccine efﬁcacy against high-grade cervical, vulvar,
or vaginal disease as well as six-month persistent infection
caused by HPV31, 33, 45, 52, and 58 in women not
previously infected with HPV following three doses of
9vHPV.42 This high efﬁcacy (90–98%) of 9vHPV in pre-
venting certain HPV-related precancers was sustained for
up to six years.43 Due to ethical concerns, 9vHPV was
compared with 4vHPV instead of a placebo control in this
study. The incidence of disease related to HPV-6, 11, 16,
and 18 was similar between both groups, with comparable
antibody responses observed, suggesting that 9vHPV is
just as effective as 4vHPV for these types. In addition,
all participants who received 9vHPV seroconverted to the
additional ﬁve HPV types (HPV31, 33, 45, 52 and 58) one
month following the last dose, and the levels of these ﬁve
additional HPV types were signiﬁcantly higher than in
4vHPV recipients.
The burden of cervical cancer and risk is different
across populations around the world. Subgroup analyses
from two Phase III double-blind randomized controlled
trials were performed among Asian and Latin American
participants to determine the population-speciﬁc vaccine
efﬁcacy.44,45 Similar high vaccine efﬁcacy (>96%) against
any grade of cervical, vulvar, and vaginal diseases, as well
as greater than 93% against six-month persistent HPV
infection, were found for both ethnic populations in
individuals who were not infected with HPV. These ﬁnd-
ings were consistent with the vaccine efﬁcacy globally,
suggesting that 9vHPV is as efﬁcacious in Asia and
Latin America.
Reactogenicity and immunogenicity
of 9vHPV
Antibody responses to 9vHPV types and the comparison
of the shared HPV genotypes (HPV6, 11, 16, and 18)
between 9vHPV and 4vHPV were investigated in clinical
studies consisting of young women (aged 16–26 years)
and young adolescent boys and girls (aged 9–15 years)
(Table 3).46–49 Almost 100% of individuals who received
9vHPV seroconverted to all vaccine types one month
following the third dose, and the antibody levels for
HPV6, 11, 16, and 18 were similar between the two
vaccine groups, suggesting that the addition of ﬁve new
types to 9vHPV did not result in interference and hence
did not alter immunogenicity to the 4vHPV types.42,50
Prior to 9vHPV licensure, three immunobridging Phase II
studies evaluated the vaccine dose formulation to ensure
the optimal formulation in terms of immunogenicity and
safety of a multivalent HPV vaccine.51
Around 77.5–100% of individuals who received three
doses of 9vHPV remained seropositive to all 9vHPV after
ﬁve years.43 When a fourth dose of 9vHPV was given to
this group of individuals, antibody responses were
1.25–4.10- and 1.65–4.88-fold higher at one week and
one month after the fourth dose, respectively, when com-
pared to the levels at one month after the third dose,
suggesting the induction of immunological memory to all
nine HPV types following the three-dose primary series.52
Higher antibody responses to all 9vHPV types were
observed in young adolescents when compared with
young adults, consistent with the earlier ﬁndings for
4vHPV and 2vHPV.50 Between male and females, the
immune responses were non-inferior at one month after
the third dose, although the geometric mean titers to all
nine HPV types were numerically lower in men who have
sex with men and in women than in heterosexual men;
geometric mean titers were lower among men who have
sex with men compared to women, which may be due to
the higher preexposure levels in these groups prior to
vaccination.53
9vHPV is also immunogenic to all nine HPV types in
young women previously vaccinated with three doses of
4vHPV.54 However, it is interesting to note that women
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who were naïve to any HPV vaccination and received
three doses of 9vHPV had higher antibody responses to
HPV31/33/45/52/58 when compared with women who
previously received three doses of 4vHPV (who were
seronegative to HPV31/33/45/52/58 after 12–36 months)
and received three doses of 9vHPV. Several mechanisms
have been proposed for this observation, including prefer-
ential activation of cross-reactive memory cells compared
to naïve cells and/or preferential activation of memory
response to HPV 16/18 L1 proteins, resulting in
a blunting of primary responses to antigenically related
HPV31/33/45/52/58 L1 proteins (the theory of original
antigenic sin; the immune system activates the memory
responses of the earlier infection/vaccination when the
epitope varies slightly, inducing faster and stronger
responses, rather than mounting another primary or sec-
ondary response to the new epitope).55 The clinical sig-
niﬁcance of this lower immune response to HPV31/33/45/
52/58 following 9vHPV vaccination in women previously
vaccinated with 4vHPV is unknown. Nevertheless, the
antibody level to these types was still several-fold higher
than natural infection and the study demonstrated that it
was safe to give 9vHPV to individuals previously vacci-
nated with 4vHPV or 2vHPV. Therefore, individuals who
wish to get additional protection to the ﬁve new types may
still require the standard two- or three-dose 9vHPV sche-
dule depending on their age and duration between doses.56
Similar to the ﬁndings of the 4vHPV and 2vHPV non-
inferiority studies, two doses of 9vHPV given six or 12
months apart to adolescent boys and girls (age 9–14 years)
generated non-inferior antibody responses (to all nine
HPV types) when compared with young women aged
16–26 years who received three doses, one month after
the last dose.57 This study was the basis of U.S. FDA
approval for a two-dose 9vHPV schedule to girls and
boys younger than age 15 years, including recommenda-
tions by the USA, European countries, and Australia.58–60
To date, more than 20,000 individuals have received
three doses of 9vHPV in Phase II and III clinical trials
(reactogenicity data summarized in Table 3). 9vHPV is
shown to be safe and generally well tolerated in partici-
pants aged 9–26 years, with a similar adverse event proﬁle
to that of 4vHPV (which is used in many countries glob-
ally as part of national immunization programs).61 The
most common adverse event from seven Phase III clinical
trials was injection-site pain, swelling, and redness, which
was more common for 9vHPV than 4vHPV with increas-
ing number of doses.61 It is important to note that the
adjuvant content in 9vHPV is more than double that of
4vHPV (0.5 vs 0.225 mg), and also has a higher VLP
antigen content (refer to Table 1). Nevertheless, most
adverse events were mild to moderate in intensity.61
Discontinuation due to adverse events and serious vaccine-
related adverse events in the clinical trials was rare.61
There were three reports of vaccine-related serious adverse
events, although the participants were later found to have
preexisting medical conditions when receiving the vac-
cine. A 10-year-old boy who has a previous history of
seasonal allergy and bronchial asthma experienced an
asthma exacerbation one day after receiving the ﬁrst
9vHPV dose.50 The boy was hospitalized, but fully recov-
ered the following day. Another participant (age 21 years)
from the same study experienced a severe headache on
the day she received the third 9vHPV dose and was hos-
pitalized the next day with neck stiffness, headache, and
fever (39.0 °C). She was discharged from the hospital two
days after receiving symptomatic treatment. It was noted
that she was bitten by a spider ﬁve days before the third
dose and was still undergoing treatment when she received
the vaccine.50 In another study, one participant (age 18
years) was hospitalized for tonsillitis two days after receiv-
ing the ﬁrst dose of 9vHPV vaccine, but fully recovered
following incision and drainage of the tonsils as well as
antibiotic treatment.54
Coadministration of 9vHPV and other adolescent vac-
cines (ie, Neisseria meningitidis serotypes A/C/Y/W-135,
diphtheria/tetanus/acellular pertussis, or diphtheria/tetanus/
acellular pertussis/inactivated poliomyelitis vaccine) to
boys and girls aged 9–14 years was also found to be safe
and immunogenic when compared with those who
received the vaccines nonconcomitantly.62,63 Together,
these data support the high safety proﬁle of this vaccine,
as well as the feasibility of concomitant administration of
9vHPV with common adolescent vaccines as a public
health strategy.
Population effect and future
directions
A long-term follow-up study to assess the effectiveness of
9vHPV for at least 14 years in participants in
Scandinavian countries (ie, Denmark, Norway, and
Sweden) from the Phase III 9vHPV efﬁcacy study
(V503-001) is currently ongoing.64 The incidence of cer-
vical precancers and cancers due to the seven oncogenic
types in the vaccine (HPV 16/18/31/33/45/52/58) will be
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compared to the estimated incidence rate in an unvacci-
nated cohort of similar age and risk level. This information
will be critical for the longevity of protection offered by
this vaccine.
9vHPV has been licensed in a number of regions including
Australia (Therapeutic Goods Association), the USA (FDA),
Canada (Health Canada), the European Union (European
Medicines Agency), and a number of countries in Asia such
as China andKorea. To our knowledge, Australia, Canada, and
the USA are using 9vHPV in their national immunization
programs, and while both Australia and Canada have school-
based programs, HPV vaccination is offered through primary
care providers in clinic-based settings in the USA.65–67
Australia recently revised their HPV vaccination schedule in
February 2018 from three doses of 4vHPV to two doses of
9vHPV in adolescent boys and girls aged 12–13 years.
Australia was one of the ﬁrst countries to introduce
a government-funded school-based HPV vaccine program
(4vHPV in 2007) with demonstrated high vaccine coverage
(around 80% for three doses) in women aged <18 years and is
associated with a signiﬁcant decrease of 0.38% in high-grade
cervical abnormalities within three years of vaccine
introduction.68 The prevalence of high-risk vaccine HPV
type declined from 22% in the prevaccine era to 1.5% among
girls aged 18–24 years, nine years after vaccine
introduction.69,70 It was postulated that the replacement of
4vHPV with 9vHPV in Australia can potentially protect
against an additional 15% and 11% of cervical cancer and
anal cancers, respectively.71 The impact of 9vHPV and the
HPV prevalence in Australia can be evaluated by “a built in
approach”which utilizes the genotyping from screening using
HPV nucleic acid testing, which was recently introduced to
replace Pap screening (largely due to the effects of HPV
vaccination on Pap abnormalities and the introduction of
a more sensitive and objective test).72 With the use of
9vHPV coupled with high vaccine coverage in a gender-
neutral vaccination program, and robust HPV screening,
Australia is likely to be the ﬁrst country to eliminate cervical
cancer (deﬁned as four new cases per 100,000 women
each year) by 2028.73 The incidence of cervical cancer is
expected to further decrease to less than one case per 100,000
women by 2066.73 The national HPV vaccine schedule in
Quebec, Canada is unique, consisting of one dose of 9vHPV
followed by a dose of 2vHPV sixmonths later to nine-year-old
girls and boys; mixed HPV vaccine schedule. The potential
cost-savings from this mixed schedule based on the lower cost
for 2vHPVare approximately $3 million per vaccinated birth
cohort comparedwith a two-dose programwith 9vHPV. These
savings could be used for catch-up vaccination in older age
groups, representing an attractive vaccination strategy, pro-
vided it is safe and equivalent protection can be achieved.74
The HPV vaccines are safe, and have similar safety proﬁles
between themixed vaccine schedule and the standard schedule
as demonstrated in several cohort studies.54,75–77 In addition,
higher immunogenicity to HPV16 and 18 (possibly due to the
unique adjuvant in 2vHPV) and lower immunogenicity to the
HPV types that are not in 2vHPV are observed in the mixed
schedule when compared with the standard 9vHPV
schedule.75 This ﬁnding is not unexpected although the clinical
signiﬁcance is unknown. Therefore, long-term follow up
including the prevalence of genital warts and other HPV-
related diseases as well as circulating HPV types following
such schedules are extremely important, and studies are in
place to monitor these outcomes.74
Several studies have found the use of 9vHPV to be highly
cost effective in high-income countries when the vaccine is
given to both boys and girls, despite the higher costs asso-
ciated with the use of 9vHPV compared with 2vHPV or
4vHPV.78–81 Although these results are largely dependent
on the vaccine cost, they were generally robust across vary-
ing assumptions based on the burden of disease, vaccine
coverage, and duration of protection including cross-
protection of 2vHPVor 4vHPV, as well as health care costs
within high-income countries. It is important to note that the
majority of the HPV-associated cancers, particularly cervical
cancer, occurs in LLMICs, and the use of HPV vaccine is
inversely proportionate to countries with the highest disease
burden; only 1.7% of women in LLMICs are estimated to
have received one dose of any HPV vaccine.82 The use of
9vHPV in LLMICs in the foreseeable future is unlikely due
to its high cost compared to either 2vHPV or 4vHPV.
However, ongoing studies are underway to examine the
efﬁcacy and immunogenicity of a single-dose HPV vaccine
(9vHPV and 2vHPV) in Costa Rica and Tanzania,
respectively,83,84 which may be a “game-changer” for
LLMICs. The continued investigation of novel strategies
such as single-dose schedules, or mixed HPV vaccine sche-
dules, will be important in the continued use and implemen-
tation of HPV vaccine in high burden settings.
Conclusion
9vHPV is safe and offers the potential to prevent 90% of
cervical cancers and a signiﬁcant proportion of HPV-
related vulvar, vaginal, and anal cancers. In high-income
countries that have high vaccine coverage and a robust
HPV screening program, the transition from 2vHPV or
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4vHPV to 9vHPVas a national immunization program will
likely further decrease the incidence of HPV-associated
diseases and the costs associated with cancer treatment
due to the additional cancer-causing types in the vaccine.
As for LLMICs, any HPV vaccine use in a national pro-
gram (demonstrated to have the highest coverage) is the
most feasible option with maximum impact on cervical
cancer morbidity and mortality. Financial and logistical
support in these countries are crucial, which will be alle-
viated with a reduced-dose schedule, particularly a single-
dose schedule if proven effective.
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